PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--ForteBio, a division of Pall Life Sciences and a leading supplier of instrumentation for accelerated drug discovery and development, today announced the launch ...

ForteBio®, Inc. has announced that it has launched two new assay modules - for high-sensitivity protein quantitation and fragment screening, respectively - for use on the company's Octet® ...

HPLC has long been regarded as the standard for antibody quantitation. It is extensively used in drug development processes to quantitate antibodies in cell culture supernatants, fed-batch flasks, and ...

ForteBio Inc., a leading supplier of label-free technology that accelerates the development of bio-therapeutic and pharmaceutical products, announced the launch of its Octet RED96 System, as well as ...

Pall ForteBio LLC, a leading supplier of instrumentation for accelerated drug discovery and development, announced the launch of the Octet K2 system, a new entry point into the Octet line of ...

Accurate protein quantitation is critical to the selection of expression strains for development and optimization of bioreactor titers in production. Traditional analytical methods include ELISA, HPLC ...

ForteBio LLC is a wholly-owned subsidiary of Pall Corp. and a division of Pall Life Sciences. ForteBio develops analytical systems that enable real-time analysis of biomolecular interactions (protein ...

MENLO PARK, Calif., March 3 /PRNewswire/ -- ForteBio(R), Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today ...

MENLO PARK, Calif. September 23, 2008 - ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development oflife science and pharmaceutic products, today announced the ...